BOLT · Bolt Biotherapeutics, Inc.

NasdaqHealthcareBiotechnology

Bolt Biotherapeutics Inc Is A Clinical-Stage Biopharmaceutical Company Developing Novel Immunotherapies For The Treatment Of Cancer. The Company Is Focused On The Clinical Development Of Bdc-4182, Its Claudin 18.2 Isac. Its Other Pipeline Programs Include Cea Isac Program A Boltbody Isac Targeting Carcinoembryonic Antigen Cell Adhesion Molecule 5, Or Cea; Pd-L1 Isac Utilizes A Novel Human Anti-Pd-L1 Antibody Conjugated To A Next-Generation Tlr7/8 Agonist Payload Via A Non-Cleavable Linker; And Bdc-3042, Its Dectin-2 Agonist Antibody Program, Developed To Repolarize Critical Cells In The Tumor Microenvironment Known As Tumor Associated Macrophages. It Operates In Single Segment.

HealthcareNasdaqUSVery Low Float

$7.55

+71.0% latest move

Price & move as of the most recent catalyst (Oct 23) - not a live quote.

FLOAT

1.4M

FREE FLOAT %

75%

SHARES O/S

1.9M

MARKET CAP

$14.8M

EXCHANGE

Nasdaq

COUNTRY

BOLT Catalyst History

Corporate DealsMerger AnnouncedOct 23, 2026 · 9:55am ET

BOLTBolt Biotherapeutics, Inc.

Be early on the next BOLT spark.

Day Trader Sniper alerts you the instant a setup like this triggers.

How it works Download Free →

Every Second Counts.
Don't Trade Without a Real-Time sparker alert.

BOLT · Bolt Biotherapeutics, Inc.

BOLT Catalyst History

Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Private Placement

Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Private Placement

Every Second Counts.Don't Trade Without a Real-Time sparker alert.

BOLT · Bolt Biotherapeutics, Inc.

BOLT Catalyst History

Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Private Placement

Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Private Placement

Every Second Counts.
Don't Trade Without a Real-Time sparker alert.